Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001437749-25-010891
Filing Date
2025-04-03
Accepted
2025-04-03 16:00:36
Documents
19
Period of Report
2025-05-23

Document Format Files

Seq Description Document Type Size
1 FORM PRE 14A sava20250323_pre14a.htm   iXBRL PRE 14A 762210
6 logocolor01.jpg GRAPHIC 17725
7 pcxy01.jpg GRAPHIC 264893
8 pcxy02.jpg GRAPHIC 350946
9 smlogo.jpg GRAPHIC 13290
  Complete submission text file 0001437749-25-010891.txt   3160571

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sava-20241231.xsd EX-101.SCH 4291
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sava-20241231_def.xml EX-101.DEF 2075
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sava-20241231_lab.xml EX-101.LAB 2461
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sava-20241231_pre.xml EX-101.PRE 1282
21 EXTRACTED XBRL INSTANCE DOCUMENT sava20250323_pre14a_htm.xml XML 166095
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-41905 | Film No.: 25809249
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)